Wen Zhu1, Tao Hai, Lei Ye, Gilbert J Cote. 1. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract
CONTEXT: Medullary thyroid carcinoma (MTC) is a cancer of the parafollicular C cells commonly caused by an inherited or acquired RET proto-oncogene mutation. Therapeutic resistance and recurrence of the disease imply the presence of cancer stem cells in MTC. OBJECTIVE: In this study, we sought to identify and characterize cancer stem cell-like cells in MTC. MAIN OUTCOME MEASURES: The characterization of stem cell properties was performed using immunostaining, flow cytometry, sphere formation assay, rederivation assay, Western blotting, and quantitative RT-PCR of defined markers of neural stem and progenitor cells. The role of ret proto-oncogene activation was assessed through RNA interference knockdown. RESULTS: CD133 positivity was identified by immunostaining patient MTC. Flow cytometry confirmed a subpopulation of CD133(+) cells in two MTC cell lines. The CD133(+) cells could be expanded by sphere formation assay, passaged multiple times, and expressed neural progenitor markers beta-tubulin 3 and glial fibrillary acidic protein. The MZ-CRC-1 cell line, which harbors a M918T RET mutation, had greater CD133(+) cell numbers and sphere-forming ability than the TT cell line, which harbors the less active C634W mutation. Sphere formation was more dependent on ret proto-oncogene activity than epidermal growth factor or fibroblast growth factor. CONCLUSION: Our data support the existence of cancer stem-like cells in MTC, which exhibit the features of self-renewal and of multiple lineage differentiation that is dependent on ret proto-oncogene receptor activity. These findings may provide new insights to develop more promising therapy for MTC.
CONTEXT: Medullary thyroid carcinoma (MTC) is a cancer of the parafollicular C cells commonly caused by an inherited or acquired RET proto-oncogene mutation. Therapeutic resistance and recurrence of the disease imply the presence of cancer stem cells in MTC. OBJECTIVE: In this study, we sought to identify and characterize cancer stem cell-like cells in MTC. MAIN OUTCOME MEASURES: The characterization of stem cell properties was performed using immunostaining, flow cytometry, sphere formation assay, rederivation assay, Western blotting, and quantitative RT-PCR of defined markers of neural stem and progenitor cells. The role of ret proto-oncogene activation was assessed through RNA interference knockdown. RESULTS: CD133 positivity was identified by immunostaining patient MTC. Flow cytometry confirmed a subpopulation of CD133(+) cells in two MTC cell lines. The CD133(+) cells could be expanded by sphere formation assay, passaged multiple times, and expressed neural progenitor markers beta-tubulin 3 and glial fibrillary acidic protein. The MZ-CRC-1 cell line, which harbors a M918TRET mutation, had greater CD133(+) cell numbers and sphere-forming ability than the TT cell line, which harbors the less active C634W mutation. Sphere formation was more dependent on ret proto-oncogene activity than epidermal growth factor or fibroblast growth factor. CONCLUSION: Our data support the existence of cancer stem-like cells in MTC, which exhibit the features of self-renewal and of multiple lineage differentiation that is dependent on ret proto-oncogene receptor activity. These findings may provide new insights to develop more promising therapy for MTC.
Authors: X Meng; M Lindahl; M E Hyvönen; M Parvinen; D G de Rooij; M W Hess; A Raatikainen-Ahokas; K Sainio; H Rauvala; M Lakso; J G Pichel; H Westphal; M Saarma; H Sariola Journal: Science Date: 2000-02-25 Impact factor: 47.728
Authors: Emmanuelle Passegué; Catriona H M Jamieson; Laurie E Ailles; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2003-09-22 Impact factor: 11.205
Authors: Martin Schlumberger; Francesca Carlomagno; Eric Baudin; Jean Michel Bidart; Massimo Santoro Journal: Nat Clin Pract Endocrinol Metab Date: 2008-01
Authors: Rozita Bagheri-Yarmand; Krishna M Sinha; Anupama E Gururaj; Zamal Ahmed; Yasmeen Q Rizvi; Su-Chen Huang; John E Ladbury; Oliver Bogler; Michelle D Williams; Gilbert J Cote; Robert F Gagel Journal: J Biol Chem Date: 2015-03-20 Impact factor: 5.157
Authors: Rozita Bagheri-Yarmand; Krishna M Sinha; Ling Li; Yue Lu; Gilbert J Cote; Steven I Sherman; Robert F Gagel Journal: Mol Cancer Res Date: 2018-12-14 Impact factor: 5.852
Authors: Parisha Bhatia; Koji Tsumagari; Zakaria Y Abd Elmageed; Paul Friedlander; Joseph F Buell; Emad Kandil Journal: World J Stem Cells Date: 2014-11-26 Impact factor: 5.326
Authors: Soon-Hyun Ahn; Ying C Henderson; Michelle D Williams; Stephen Y Lai; Gary L Clayman Journal: J Clin Endocrinol Metab Date: 2013-12-03 Impact factor: 5.958